

### **Amendments to the Claims**

This listing of the claims will replace all prior versions, and listings, of the claims in the application.

### **Listing of Claims**

#### **Claims 1-18 (canceled)**

19. (currently amended) A pharmaceutical composition of matter comprised of an effective inflammation-alleviating amount of a mixture of Free-B-Ring flavonoids and flavans comprising at least baicalin and catechin and a pharmaceutically or cosmetically acceptable carrier suitable for administration to the skin selected from the group consisting of a lotion, a gel, an ointment, a cream, a soap and an emulsion, wherein the pharmaceutical or cosmetic composition alleviates inflammation when applied to the skin.

20. (currently amended) The pharmaceutical composition of claim 19 wherein the ratio of Free-B-Ring flavonoids to flavans in said composition is selected from the range of 99:1 Free-B-Ring flavonoid:flavan to 1:99 of Free-B-Ring flavonoid:flavan.

21. (currently amended) The pharmaceutical composition of 20 wherein the ratio of Free-B-Ring flavonoid:flavan in the composition of matter is about 20:80.

#### **Claims 22-23 (canceled)**

24. (currently amended) The pharmaceutical composition of claim 19 wherein said Free-B-Ring flavonoids and said flavans are obtained by organic synthesis or are isolated from a plant.

25. (currently amended) The pharmaceutical composition of claim 24 wherein said Free-B-Ring flavonoids and said flavans are isolated from a plant part selected from the group consisting of stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers and other reproductive organs, leaves and other aerial parts.

26. (currently amended) The pharmaceutical composition of claim 24 wherein said Free-B-Ring flavonoids are isolated from a plant family selected from the group consisting of *Annonaceae, Asteraceae, Bignoniaceae, Combretaceae, Compositae, Euphorbiaceae, Labiateae, Lauraceae, Leguminosae, Moraceae, Pinaceae, Pteridaceae, Sinopteridaceae, Ulmaceae* and *Zingiberacea*.

27. (currently amended) The pharmaceutical composition of claim 24 wherein said Free-B-Ring flavonoids are isolated from a plant genus selected from the group consisting of *Desmos, Achyrocline, Oroxylum, Buchenavia, Anaphalis, Cotula, Gnaphalium, Helichrysum, Centaurea, Eupatorium, Baccharis, Sapium, Scutellaria, Molsa, Colebrookea, Stachys, Origanum, Ziziphora, Lindera, Actinodaphne, Acacia, Derris, Glycyrrhiza, Millettia, Pongamia, Tephrosia, Artocarpus, Ficus, Pityrogramma, Notholaena, Pinus, Ulmus and Alpinia*.

28. (currently amended) The pharmaceutical composition of claim 24 wherein said flavans are isolated from a plant species selected from the group consisting of the *Acacia catechu, Acacia concinna, Acacia farnesiana, Acacia Senegal, Acacia speciosa, Acacia arabica, A. caesia, A. pennata, A. sinuata, A. mearnsii, A. picnantha, A. dealbata, A. auriculiformis, A. holoserecia* and *A. mangium*.

29. (currently amended) The pharmaceutical composition of claim 24 wherein said Free-B-ring flavonoids are isolated from a plant or plants in the *Scutellaria* genus of plants and said flavan is isolated from a plant or plants in the *Acacia* genus of plants.

30. (currently amended) The pharmaceutical composition of claim 19 further comprising a pharmaceutically acceptable excipient and optionally an adjuvant or a wherein the carrier is a lotion.

Claim 31 (canceled)

32. (currently amended) The pharmaceutical composition of claim 19 where said composition is formulated in a regular or controlled releasing vehicle.

Claims 33-45 (canceled)

46. (currently amended) The pharmaceutical composition of claim 60 wherein said inflammatory diseases and conditions of the skin are mediated by diseases and conditions selected from the group consisting of thermal burns, acne, topical wounds, minor inflammatory conditions caused by fungal, microbial and viral infections, vitilago, systemic lupus erythematosus, psoriasis, carcinoma, melanoma, as well as other mammal skin cancers, skin damage resulting from exposure to chemicals, heat, wind and dry environments, wrinkles, saggy skin, lines and dark circles around the eyes, hyperpigmentation, age spots, dermatitis and other allergy related conditions of the skin.

47. (currently amended) The pharmaceutical composition of claim 19 for use in the treatment of inflammatory conditions of the and skin damage resulting from exposure to skin irritants.

48. (currently amended) The pharmaceutical composition of claim 47 wherein the ratio of Free-B-Ring flavonoids<sub>§</sub> to flavans<sub>§</sub> in said composition is selected from the range of 99:1 Free-B-Ring flavonoid:flavan to 1:99 of Free-B-Ring flavonoid:flavan.

49. (currently amended) The pharmaceutical composition of 48 wherein the ratio of Free-B-Ring flavonoid:flavan in the composition of matter is about 20:80.

50. (currently amended) The pharmaceutical composition of claim 47-19 further comprising a pharmaceutically acceptable excipient and optionally an adjuvant or a wherein the carrier is a cream.

Claim 51 (canceled)

52. (currently amended) The pharmaceutical composition of claim 47 where said composition is formulated in a regular or controlled releasing vehicle.

53. (currently amended) The pharmaceutical composition of claim-19 for use in the treatment of inflammation sunburns and skin damage resulting from exposure to UV radiation.

54. (currently amended) The pharmaceutical composition of claim 53 wherein the ratio of Free-B-Ring flavonoidss to flavanss in said composition is selected from the range of 99:1 Free-B-Ring flavonoid:flavan to 1:99 of Free-B-Ring flavonoid:flavan.

55. (currently amended) The pharmaceutical composition of 54 wherein the ratio of Free-B-Ring flavonoid:flavan in the composition of matter is about 20:80.

Claims 56-57 (canceled)

58. (currently amended) The pharmaceutical composition of claim 53 where said composition is formulated in a regular or controlled releasing vehicle.

Claim 59 (canceled)

60. (currently amended) The pharmaceutical composition of claim-19 for use in the treatment of cyclooxygenase (COX) and lipoxygenase (LOX) mediated inflammatory diseases and conditions of the skin.

Claim 61 (canceled)

Appl. No. 10/817,330  
Amdt. dated March 3, 2010  
Reply to Office Action of September 3, 2009

62. (currently amended) The pharmaceutical composition of claim-64 60 wherein the ratio of Free-B-Ring flavonoids<sub>§</sub> to flavans<sub>§</sub> in said composition is selected from the range of 99:1 Free-B-Ring flavonoid:flavan to 1:99 of Free-B-Ring flavonoid:flavan.

63. (currently amended) The pharmaceutical composition of 62 wherein the ratio of Free-B-Ring flavonoid:flavan in the composition of matter is about 20:80.

Claims 64-65 (canceled)

66. (currently amended) The pharmaceutical composition of claim-64 60 where said composition is formulated in a regular or controlled releasing vehicle.